While OS results are still pending, and considering the potential cross-over effect (at the time of cutoff, 59% of patients in the chemotherapy arm had crossed over to anti-PD(L)1 agents either within or outside the trial), this is a practice-changing trial and its results probably establish pembrolizumab as a new first-line standard in MSH-I/MMRd CRC [35]. The gene discussed is CD274; the disease is colorectal carcinoma.